Brief: Adc Therapeutics Announces Updated Data From Lotis-7 Phase 1B Clinical Trial Of Zynlonta
03/12/2025 12:32
Dec 3 (Reuters) - ADC Therapeutics SA ADCT.N: ADC THERAPEUTICS ANNOUNCES UPDATED DATA FROM LOTIS-7 PHASE 1B CLINICAL TRIAL OF ZYNLONTA® IN COMBINATION WITH BISPECIFIC ANTIBODY SUPPORTING POTENTIAL BEST-IN-CLASS REGIMEN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ADC THERAPEUTICS SA - LOTIS-7 TRIAL ON TRACK FOR COMPLETE ENROLLMENT IN 1H 2026 Source text: ID:nPn2vVl98a Further company coverage: ADCT.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million